Medical researchers have identified more than a thousand cases of Lyme Disease in Europe and suggest the vaccine could be a better bet than the one currently available, the Lancet Medicine article Medical Research Council (MRC) announced today.
The report, which looks at the number of cases of the bacterial infection over the past two years in the UK and France, also looked at how many of the infections were linked to food.
It found that, compared to cases in the United Kingdom, France and Germany, the number in France is at the lowest level since 2000.
It was also revealed that only one case in the US has been linked to a meat product, while the majority of cases in France were linked more to dairy products.
There is currently no vaccine for Lyme disease, but MRC’s research team are working on a new one that has been shown to be effective in the past.
In a statement, the MRC said that it has been analysing data from its research programme for the past five years, and found there is an “extraordinary” link between cases of antibiotic-resistant infections and the consumption of animal products.
This is a problem that is affecting many countries across Europe, the report said.
“There is an urgent need for a vaccine to be developed, because of the global pandemic and our need to address the problem of antibiotic resistance,” said Dr Chris Larkin, the chief executive of the MRS Centre for Epidemiology and Prevention.
“However, the development of a safe vaccine is not at the moment of the agenda, and we believe a combination of antibiotics, vaccines and a single vaccine will be able to achieve this.”
Larkin added that this research has led to the recommendation of an expanded use of animal agriculture for food.
“A major problem for the NHS is that the vast majority of our antibiotics are consumed in the form of antibiotics for food,” he said.
Larkin also said that the MCRs research team would be working with other researchers to explore the potential for a new vaccine in the coming years.
He said the new research will also focus on how the use and abuse of antibiotics impacts the immune system, which is already at risk from the antibiotic-resistance pandemic.
“This research will have to be driven by a broader perspective,” he added.
“It will not be easy, but we need to be able for a good vaccine to come out of this.”
The MRC also said there were no new studies underway in France, Germany or the United States to test whether a new antibiotic-based vaccine could help treat the spread of the infection.
The MRS said there is a high incidence of antibiotic resistant infections in France.
“It is important that a vaccine is developed that is safe and effective and does not have side effects,” said Larkin.
“For this reason, the team will be working closely with other experts to identify research that might be able with a new compound to help address the transmission of this infection.”
Read more at New Scientist